Nuclide Tx named start-up to watch in 2026
Chemical & Engineering News announce their 10 start-ups to watch in 2026
Nuclide Tx and pharmAI announce strategic collaboration
The two companies will co-develop a novel radiotheranostic platform targeting hard to treat cancers
NTx co-founder featured by Times Higher Education
Tim Witney featured in their spotlight guide 'A step-by-step guide to commercialising your research'
World Cancer Day 2026
King's College London sat down with our CSO, Prof. Tim Witney, for World Cancer Day.
Latest press release
Read our press release detailing the conclusion of our recent funding round.
Launch announcement
Nuclide Therapeutics secures £5 million investment to spearhead first-in-human clinical trials.
